183 related articles for article (PubMed ID: 36362074)
1. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
2. Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale.
Attardi LD; Boutelle AM
Cell Death Differ; 2024 Feb; 31(2):133-135. PubMed ID: 38151545
[No Abstract] [Full Text] [Related]
3. A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.
Dunsche L; Ivanisenko N; Riemann S; Schindler S; Beissert S; Angeli C; Kreis S; Tavassoli M; Lavrik I; Kulms D
Cell Death Dis; 2023 Dec; 14(12):831. PubMed ID: 38097548
[TBL] [Abstract][Full Text] [Related]
4. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Kajiwara T; Nishina T; Yamashita R; Nakamura Y; Shiozawa M; Yuki S; Taniguchi H; Hara H; Ohta T; Esaki T; Shinozaki E; Takashima A; Yamamoto Y; Yamazaki K; Yoshino T; Hyodo I
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958346
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY; Heng WS; Teoh SSH; Lwin YY; Cheah SC
J Transl Med; 2023 Nov; 21(1):786. PubMed ID: 37932756
[TBL] [Abstract][Full Text] [Related]
6. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer.
Otegui N; Houry M; Arozarena I; Serrano D; Redin E; Exposito F; Leon S; Valencia K; Montuenga L; Calvo A
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370686
[TBL] [Abstract][Full Text] [Related]
7. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.
Shen J; Wang Q; Mao Y; Gao W; Duan S
MedComm (2020); 2023 Jun; 4(3):e288. PubMed ID: 37256211
[TBL] [Abstract][Full Text] [Related]
8. Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer.
Chen J; Liu Z; Wu Z; Li W; Tan X
Front Oncol; 2023; 13():1132424. PubMed ID: 37251940
[TBL] [Abstract][Full Text] [Related]
9. Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial.
Lam-Ubol A; Sukhaboon J; Rasio W; Tupwongse P; Tangshewinsirikul T; Trachootham D
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175527
[No Abstract] [Full Text] [Related]
10. PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.
Paz MM; Ferretti GDS; Martins-Dinis MMC; Ferreira BIS; Faier-Pereira A; Barnoud T; Moreira OC; Silva JL; Cordeiro Y; Rangel LP
Front Mol Biosci; 2023; 10():1165132. PubMed ID: 37101558
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial Network of Transcriptional and miRNA Regulation in Colorectal Cancer.
Kumar R; Mahmoud MM; Tashkandi HM; Haque S; Harakeh S; Ponnusamy K; Haider S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982429
[TBL] [Abstract][Full Text] [Related]
12. Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness.
Sengupta S; Ghufran SM; Khan A; Biswas S; Roychoudhury S
Cancer Cell Int; 2022 Dec; 22(1):416. PubMed ID: 36567312
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
16. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.
Shetzer Y; Molchadsky A; Rotter V
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27235476
[TBL] [Abstract][Full Text] [Related]
18. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.
Roszkowska KA; Piecuch A; Sady M; Gajewski Z; Flis S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362074
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
